Marlon Liyanage, PharmD

Clinical Pharmacologist
Pfizer Inc

Poster(s):

• (S-076) Exposure-Response Characterization of the Safety Profile for a Novel KAT6 Inhibitor, PF-07248144, For Use In Dose Optimization During a Phase 1 First-in-Patient Study
  Sunday, October 19, 2025

  7:00 AM - 5:00 PM MDT